Skip to main content
Premium Trial:

Request an Annual Quote

Former Sequana CFO Joins Ventana Genetics


SALT LAKE CITY--Ventana Genetics here announced that M. Scott Salka is the biotech company's new CEO. Salka joined Ventana from genomics company Sequana Therapeutics, where he was vice president of operations and chief financial officer. At Sequana, Salka directed strategic planning and corporate development efforts, which included raising capital and structuring industry collaborations. He participated in Sequana's startup in 1993 and was instrumental in raising over $25 million in three rounds of private funding and nearly $50 million in two public equity financings, as well as negotiating four industry collaborations worth up to $250 million.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.